The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

Teme:

Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. od Seyed Reza Mousavi (13223324)

Teme:

Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

Teme:

Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

Teme:

Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. od Seyed Reza Mousavi (13223324)

Teme:

Occupational and other individual exposure factors. od Paul Le Turnier (7829654)

Teme:

Flow chart of participants in leptospirosis serological survey. od Paul Le Turnier (7829654)

Teme:

Water collection sources and usages. od Paul Le Turnier (7829654)

Teme:

Microscopic agglutination test results. od Paul Le Turnier (7829654)

Teme:

Sociodemographic data and residence characteristics. od Paul Le Turnier (7829654)

Teme:

Characteristics of participants. od Karen Klein (6650600)

Teme:

Database and Dictionary. od Karen Klein (6650600)

Teme:

Anticipated barriers to MNH-EPI-COS adoption in observational research studies and surveillance in the context of epidemics. od Karen Klein (6650600)

Teme:

Acceptability for the inclusion of outcomes and definitions and feasibility of data collection for each outcome. od Karen Klein (6650600)

Teme:

pgph.0005474.t005 - od Karen Klein (6650600)

Teme:

Overall acceptability of the MNH-EPI-COS. od Karen Klein (6650600)

Teme: